Navigation Links
Cedars-Sinai immunotherapy expert honored for work in kidney transplantation
Date:8/7/2014

LOS ANGELES (Aug. 8, 2014) Ashley Anh Vo, PharmD, administrative director of the Transplant Immunotherapy Program at the Comprehensive Transplant Center at Cedars-Sinai, has been named the 2014 Clinician of Distinction by the American Society of Transplantation for her work in developing anti-rejection drug protocols for patients.

"This prestigious award recognizes Dr.Vo's clinical excellence and the creative scholarship she brings to the field of transplantation," said Andrew S. Klein MD, FACS, MBA, director of the Cedars-Sinai Comprehensive Transplant Center. "This is a unique achievement that represents her dedication and tireless work on behalf of transplant patients."

Vo received the award at the recent World Transplant Congress in San Francisco, where Cedars-Sinai kidney transplant clinicians and researchers contributed nearly 30 abstracts and presentations to the international gathering. One of the most highly anticipated presentations involved preliminary research of a new anti-rejection drug known as C1-INH by Stanley C. Jordan, MD, director of kidney transplantation and transplant immunology at Cedars Sinai. Patients in the small trial who received C1-INH after transplantation developed fewer complications.

Vo's research in immunotherapy began in 1994 when she became the transplant pharmacist for Cedars-Sinai and joined a National Institutes of Health investigation headed by Jordan. Since then, Vo and Jordan have collaborated extensively, producing the 2004 landmark study that identified new anti-rejection treatments.

That study tested IVIG, intravenous immunoglobulin, as an effective therapy for lowering a patient's level of HLA antibodies, which can cause a patient's body to reject a transplanted organ. Patients who have been pregnant, been on kidney dialysis or received many blood transfusions often develop HLA antibodies, making it very hard for them to have a successful kidney transplant.

"Dr. Vo has played a key role in our research identifying how IVIG treatment significantly reduces the long amount of time a patient can remain on dialysis, suffering, waiting for a suitable transplant because their HLA antibody levels put them at a high risk of organ rejection," said Jordan. "Her work has been an important asset to the entire field of organ transplantation."


'/>"/>

Contact: Laura Coverson
laura.coverson@cshs.org
310-423-5215
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. California Healthcare Institute Adds Executives from Gilead Sciences, Cedars-Sinai and Versant Ventures to Its Board
2. Cedars-Sinai study identifies heart-specific protein that protects against arrhythmia
3. Cedars-Sinai surgeon and policymaker honored for work in liver disease and transplantation
4. Grant supports Cedars-Sinai study of possible links between air pollution and brain cancer
5. Cedars-Sinai clinical trial studies vaccine targeting cancer stem cells in brain cancers
6. Update: 50 percent of patients in Cedars-Sinai brain cancer study alive after 5 years
7. Prominent Cedars-Sinai medical physicist receives highest honor from distinguished association
8. Cedars-Sinai opens first-of-its-kind trial in western US for metastatic carcinoid cancer patients
9. Heart valve repair innovator receives Cedars-Sinai Heart Institutes Corday Prize in Heart Research
10. Cedars-Sinai study: Obesity may be linked to microorganisms living in the gut
11. Nobel laureate Roger Tsien, Ph.D., keynotes Cedars-Sinai nanomedicine conference March 15, 16
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet ... in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition ... lives. “We are prolonging life 6 years in the last 3 decades,” says ...
(Date:12/2/2016)... ... 02, 2016 , ... Universal Medical Systems, Inc. (UMS) the ... company to offer robotic imaging to veterinary medicine is sponsoring the appearance of ... the American Association of Equine Practitioners 62nd Annual Convention from December 4-6, 2016 ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Yisrayl Hawkins, at ... into how this current generation fits into Bible Prophecy. Yisrayl says this generation, known ... pointing to this conclusion, showing how the details line up exactly with Bible Prophecy ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)...  PipelineRx, a leading medication management technology company ... of its SaaS-based telepharmacy platform, PowerGridRx™ , ... Midyear Clinical Meeting and Exhibition, December 5-7 in ... 300 hospital clients nationally, the Company is a ... dramatically improve pharmacy operations, enhance patient safety, and ...
(Date:12/2/2016)... 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today announced ... ("PSI").  The combination of Texas -based Maxor ... PSI bring together both company,s clinical expertise and high-touch patient ... industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
Breaking Medicine Technology: